Impact Stories

Latest Impact Report: Non-calcium-based phosphate binders

Around six people are diagnosed with kidney failure each day, a threefold increase from two decades ago. A serious complication that can occur in the later stages of chronic kidney disease is hyperphosphataemia, which can lead to life-threatening consequences including cardiovascular calcification, bone diseases and secondary hyperparathyroidism.

Typical first-line treatment for hyperphosphataemia utilises calcium-based phosphate binders, subsidised by the Ministry of Health, Singapore. In cases of poor control or intolerance to these binders, patients may be switched to non-calcium-based phosphate options, as an additional therapy or as a standalone treatment. This demonstrated a high clinical need to make subsidised non-calcium-based phosphate binders available, to drive appropriate care.

Published December 2024

Read our report